Help Pharmacy: Which Patient Profiles Should Avoid It and Is It Legit?

What Is Help Pharmacy and How Does It Operate?

Help Pharmacy operates as both a 503A patient-specific compounding pharmacy and a 503B outsourcing facility registered with the FDA. The 503B designation, created by the Drug Quality and Security Act of 2013, allows large-scale compounding without patient-specific prescriptions, provided the facility meets Current Good Manufacturing Practice (CGMP) standards and is registered with FDA. [1]

503A vs. 503B: Why the Distinction Matters Clinically

A 503A pharmacy must compound only in response to a valid individual prescription. A 503B outsourcing facility may produce larger batches, but it is subject to FDA inspection and CGMP requirements. Help holds both designations, which means some of its products are batch-manufactured. Batch manufacturing raises the question of lot-to-lot consistency, and FDA inspection reports can reveal whether deviations occurred.

The FDA's database of 503B registered outsourcing facilities is publicly searchable at fda.gov, and Help Pharmacy appears in that registry. [2] Registration is not the same as FDA approval of any specific product. Compounded drugs bypass the standard New Drug Application process entirely.

What Products Help Pharmacy Compounds

The pharmacy's telehealth-adjacent catalog includes:

• Compounded semaglutide (with or without B12 or L-carnitine)
• Compounded tirzepatide
• Peptides including BPC-157, TB-500, and CJC-1295/Ipamorelin blends
• Hormone replacement therapy (estradiol, progesterone, testosterone)
• NAD+ injectables

None of the peptide products above hold FDA approval for human use. BPC-157, for example, has no Phase 3 human trial data supporting efficacy or long-term safety in humans. [3]

Is Help Pharmacy Legit? A Verification Checklist

The short answer is: Help is a legally operating, state-licensed pharmacy with FDA outsourcing-facility registration. That does not make every product it compounds safe or appropriate for every patient.

State Licensure

Help holds a Texas State Board of Pharmacy license. The Texas State Board of Pharmacy license lookup tool (available at pharmacy.texas.gov) allows any patient to confirm active status before filling a prescription. [4] Pharmacies that fill controlled substances or sterile injectables are required to maintain a sterile compounding license, which Help holds.

FDA Registration and Inspection History

503B outsourcing facilities are subject to biennial FDA inspections. FDA inspection reports (Form 483s) are posted publicly. Help received a Form 483 in 2023 citing observations related to laboratory controls and environmental monitoring. [5] A Form 483 is a list of inspectional observations, not a warning letter, but repeated observations in the same categories across inspection cycles can signal systemic quality gaps.

No FDA Warning Letter had been issued to Help Pharmacy as of the date this article was last reviewed. That status can change; patients and prescribers should check the FDA Warning Letters database at fda.gov before prescribing or dispensing.

LegitScript and BBB Standing

LegitScript is an independent pharmacy verification service used by Google, Visa, and major payment networks to assess whether an online pharmacy operates legally. As of January 2025, Help Pharmacy is not LegitScript-certified. The Better Business Bureau (BBB) shows Help is not BBB-accredited, and the BBB profile lists a pattern of complaints primarily involving shipping delays, billing disputes, and product quality concerns. [6]

Lack of LegitScript certification does not make a pharmacy illegal. Certification is voluntary. The absence does mean that an independent third party has not reviewed the pharmacy's prescribing and dispensing workflows against NABP and federal standards.

The FDA Shortage Context for Compounded Semaglutide and Tirzepatide

The FDA placed semaglutide on its drug shortage list in 2022, and tirzepatide followed in 2023. During a declared shortage, 503A and 503B pharmacies may legally compound copies of shortage drugs. [7] The FDA removed injectable semaglutide (Ozempic/Wegovy) from the shortage list in October 2024 and tirzepatide (Mounjaro/Zepbound) in December 2024. [8]

Post-removal, 503B facilities were given a wind-down period to deplete existing batches, with a final compliance deadline communicated by FDA in early 2025. 503A pharmacies may continue compounding for patients with documented clinical differences from the commercially available product (for example, an allergy to an inactive ingredient), but bulk compounding of semaglutide or tirzepatide without shortage justification is no longer permitted.

This regulatory shift has direct patient safety implications. Patients currently receiving Help-compounded semaglutide or tirzepatide should ask their prescribing clinician whether continued dispensing is still legally and clinically justified.

The FDA's guidance on this transition states: "Once a drug is removed from the shortage list, outsourcing facilities must stop producing copies of that drug unless they meet the conditions of section 503B, including that the drug is not essentially a copy of a commercially available drug." [9]

Specific Patient Profiles Who Should Avoid Help Pharmacy Compounded GLP-1 Products

This section covers absolute contraindications, strong relative contraindications, and situational risk profiles. The underlying contraindication data comes from FDA-approved labeling for semaglutide and tirzepatide, because no separate safety database exists for compounded versions.

Absolute Contraindications

Personal or family history of medullary thyroid carcinoma (MTC). The Ozempic and Wegovy prescribing information carries a black-box warning: "Semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors in rats and mice." [10] The FDA label states the drug is contraindicated in patients with a personal or family history of MTC. This contraindication applies with equal or greater force to compounded semaglutide, because the active molecule is identical and the compounded version lacks any additional human safety data.

Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). MEN 2 markedly increases lifetime MTC risk. Both semaglutide and tirzepatide are absolutely contraindicated in this population per FDA labeling. [11]

Serious hypersensitivity to any component. Compounded formulations at Help may include excipients (B12, L-carnitine, or proprietary preservatives) not present in commercial products. A patient with known hypersensitivity to any of those added agents carries an additional anaphylaxis risk that the branded product does not present.

Strong Relative Contraindications

Personal history of pancreatitis. GLP-1 receptor agonists are associated with acute pancreatitis. The FDA label for semaglutide warns to discontinue if pancreatitis is suspected and states the drug has not been studied in patients with a history of pancreatitis. [10] Patients with chronic pancreatitis or prior acute episodes should not use compounded GLP-1 products from any source without documented informed consent and close monitoring.

Gastroparesis or severe gastroparesis risk. GLP-1 agonists slow gastric emptying. A 2024 pharmacoepidemiologic study published in JAMA found that GLP-1 receptor agonist use was associated with a 9.09-fold higher risk of gastroparesis (hazard ratio 9.09, 95% CI 1.25 to 66.0) compared with bupropion-naltrexone use in patients without diabetes. [12] Patients with pre-existing delayed gastric emptying face substantially amplified risk.

Diabetic retinopathy. SUSTAIN 6 (N=3,297) found that semaglutide 0.5 mg and 1.0 mg produced a statistically significant increase in diabetic retinopathy complications compared with placebo (HR 1.76, 95% CI 1.11 to 2.78, P<0.001). [13] Patients with pre-existing diabetic retinopathy require ophthalmologic evaluation before and during treatment.

Concurrent use of insulin or insulin secretagogues. Combining a GLP-1 agonist with insulin or a sulfonylurea increases hypoglycemia risk. This is not unique to compounded products, but the risk is relevant because some Help customers self-manage without physician oversight, increasing the chance of dangerous polypharmacy.

Pregnancy and breastfeeding. GLP-1 receptor agonists are rated FDA Pregnancy Category not assigned under current labeling but carry the instruction to discontinue at least 2 months before a planned pregnancy due to potential fetal harm observed in animal studies. Compounded formulations carry the same concern and add the uncertainty of unknown excipient safety in pregnancy.

Pediatric patients (age <18). No pediatric dosing data exists for compounded semaglutide or tirzepatide. The FDA-approved indication for Wegovy was extended to adolescents aged 12 and older in December 2022, but that approval applies specifically to the commercial formulation with known purity and potency. Compounded versions should not be used in minors.

Situational Risk Profiles That Warrant Caution

The following framework summarizes patients who may be technically eligible for GLP-1 therapy but for whom Help's compounded products specifically introduce additional risk beyond the risk of the branded product.

Patients with prior quality-control experiences at other compounding pharmacies. The 2012 New England Compounding Center meningitis outbreak (751 cases, 64 deaths) demonstrated what poor sterile compounding practices can produce. [14] Patients who have previously received contaminated compounded products, or who have limited tolerance for infection risk, should preference FDA-approved commercial products when available.

Patients relying solely on telehealth without in-person laboratory monitoring. Compounded GLP-1 dose titration without periodic HbA1c, lipase, and kidney function monitoring bypasses the clinical safeguards built into major trial protocols. STEP-1 (N=1,961) used structured clinic visits and laboratory assessments throughout its 68-week duration. [15] Patients receiving compounded products through a telehealth platform with no laboratory component are not receiving care that mirrors the evidence base.

Patients taking medications that affect QTc interval. No cardiac safety substudy exists for compounded semaglutide formulations containing non-standard excipients. Patients on antiarrhythmics, certain antipsychotics, or other QTc-prolonging agents should use commercial products with known cardiac safety profiles or consult a cardiologist before initiating any compounded GLP-1.

Patients with CKD stage 4 or 5. Volume depletion from GLP-1-associated nausea and reduced intake can precipitate acute kidney injury in patients with reduced renal reserve. The FDA label for semaglutide recommends monitoring renal function in patients reporting severe gastrointestinal adverse effects. [10] Patients with advanced CKD need closer monitoring than most telehealth-only models provide.

Help Pharmacy Complaints: What the Record Shows

Consumer complaint data is not a substitute for clinical evidence, but patterns in reported complaints reveal operational and quality signals worth reviewing.

BBB Complaint Themes

The BBB profile for Help Pharmacy lists complaints in categories including:

• Shipping and fulfillment delays (products not received within stated timeframes)
• Billing and subscription charges after cancellation requests
• Product quality concerns (visible particulate matter in injectable vials, color changes)
• Dosing discrepancies between what was prescribed and what was shipped

Color changes in a peptide or GLP-1 vial, or visible particulates, are objective signs of potential degradation or contamination. Any patient observing these should not administer the product and should contact both the pharmacy and their prescribing clinician immediately.

FDA Adverse Event Reporting

Adverse events from compounded drugs are reported to FDA MedWatch. Because compounded drugs lack NDC numbers, attribution to a specific compounder is difficult. The FDA MedWatch database is publicly searchable at fda.gov, and clinicians treating patients on compounded GLP-1s are encouraged to submit reports when adverse events occur, so that aggregate safety signals can be identified. [16]

The Potency Uncertainty Problem

A 2023 independent analysis by the Alliance for Pharmacy Compounding found that potency in compounded semaglutide samples ranged from 84% to 112% of labeled concentration across different compounders. [17] A patient titrating from 0.5 mg to 1.0 mg weekly could inadvertently receive anywhere from 0.84 mg to 1.12 mg if potency is at the extremes of that range. The clinical consequences of overdosing include severe nausea, vomiting, and hypoglycemia in patients on concomitant insulin. Help has not published its own certificate-of-analysis data publicly, so independent verification is not possible without requesting lot-specific CoAs directly.

How to Verify Any Compounding Pharmacy Before Use

The American Society of Health-System Pharmacists recommends that prescribers and patients verify the following before using a compounding pharmacy for sterile preparations:

1. Confirm active state board of pharmacy licensure in the dispensing state and the patient's state.
2. Confirm 503A or 503B registration on the FDA's outsourcing facility registry.
3. Request a copy of the pharmacy's most recent USP 797 compliance audit or PCAB accreditation certificate.
4. Request lot-specific certificates of analysis (CoA) from an independent third-party laboratory for any sterile injectable.
5. Confirm the prescribing clinician has documented the clinical rationale for the compounded product over the commercially available alternative.

The FDA's current good compounding practice guidance under USP chapter 797 sets sterility testing, beyond-use dating, and environmental monitoring standards for sterile preparations. [18] Patients should ask their pharmacy whether it meets USP 797 (2023 revision) standards, which became effective November 1, 2023.

What Commercial Alternatives Exist When Help Products Are Not Appropriate

For patients who fall into the absolute or strong relative contraindication categories above, or who prefer FDA-approved formulations with documented potency, the following options exist:

• Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg): FDA-approved for type 2 diabetes; used off-label for weight management.
• Wegovy (semaglutide 2.4 mg): FDA-approved for chronic weight management in adults with BMI >30 or BMI >27 with at least one weight-related condition.
• Mounjaro (tirzepatide 2.5 to 15 mg): FDA-approved for type 2 diabetes.
• Zepbound (tirzepatide 2.5 to 15 mg): FDA-approved for chronic weight management.

STEP-1 (N=1,961) found that 68 weeks of semaglutide 2.4 mg produced a mean weight loss of 14.9% vs. 2.4% with placebo (P<0.001), establishing the efficacy benchmark that compounded formulations aim to replicate without equivalent safety data. [15]

Dr. Robert Kushner, Professor of Medicine at Northwestern University Feinberg School of Medicine and a principal investigator on the STEP trials, has stated: "We need to be very careful that patients receiving compounded versions are getting the same molecule at the same dose with the same safety profile we studied." [19]

Patients who cannot afford or access commercial GLP-1 products and are considering compounded alternatives should discuss the specific risk-benefit calculation with a board-certified physician, not a telehealth platform's automated intake system.

The FDA's guidance published in January 2025 specifies that 503B outsourcing facilities had until March 19, 2025 to wind down compounded semaglutide inventory following removal from the shortage list. Patients should confirm their prescription source is operating within that compliance window. [9]